GenSci139 approved for clinical trial in solid tumors for Changchun GeneScience Pharmaceutical

Changchun High & New Technology Industry Group announced its subsidiary, Changchun GeneScience Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for a clinical trial of GenSci139 for injection. The drug will be tested as a monotherapy in patients with advanced solid tumors.

GenSci139 is an independently developed bispecific antibody-drug conjugate (BsADC) targeting both EGFR and HER2 receptors. These targets are prominent in current anti-tumor drug development, with HER2-targeted ADC drugs already approved globally. The drug utilizes a proprietary linker technology designed for high stability and potent cytotoxic activity, aiming to enhance tumor cell killing and improve safety.

The company anticipates that successful clinical trial progression will broaden its business scope, optimize its product portfolio, and strengthen its core competitiveness. However, it also cautioned investors about the inherent risks associated with pharmaceutical product development, including long development cycles and uncertainty in clinical trial outcomes.